Pharmaceuticals News and Research

RSS

Biostar Pharmaceuticals' new drug application granted clearance for clinical trials

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced that the Chinese Military Drug Administration has granted clearance to begin clinical trials on the Company's new drug application, the Zushima Analgesic Aerosol Spray.

7 Oct 2009

Cipher Pharmaceuticals enrolls first patient in Phase III study of CIP-ISOTRETINOIN

Cipher Pharmaceuticals Inc. today announced that it has enrolled the first patient in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne.

7 Oct 2009

Arizona Heart Institute partners with Arizona Research Center for the advancement of cardiovascular therapies

Arizona Heart Institute, a world leading medical facility specializing in diagnosis, treatment and prevention of heart and vascular disease, and Arizona Research Center, a dedicated provider of clinical research studies, announce a partnership in the advancement of cardiovascular therapies.

7 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

Aryx Therapeutics to raise up to $35 million from sale of its common stock

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has secured a committed equity financing facility under which it may sell up to $35 million of shares of its common stock to Commerce Court Small Cap Value Fund, Ltd. (“Commerce Court”) over a 24 month period. The maximum number of shares that can be sold by ARYx is specified in the agreement. ARYx is not obligated to utilize any of the $35 million facility and remains free to enter into and consummate other equity and debt financing transactions.

7 Oct 2009

Tranziger forms global advisory and business team to execute strategic transactions

Tranziger Limited announced today the formation of its global advisory and business team to advise and assess companies in the life sciences and healthcare sectors to execute strategic transactions and realise and optimise value from their portfolios in these turbulent times. Tranziger Limited is headquartered in London, England, UK and has offices in Washington, DC and Edinburgh.

7 Oct 2009

Roche and Genentech obtain license to use SurModics’ drug delivery system

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has signed a License and Development Agreement with Roche and Genentech, Inc., a wholly-owned member of the Roche Group.

7 Oct 2009

CBI announces agenda for upcoming Biotech/Pharma Finance and Accounting Forum in San Francisco

The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce the full agenda for the upcoming Biotech/Pharma Finance and Accounting Forum in San Francisco on November 19, 2009.

7 Oct 2009

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009

Shire publishes efficacy study results of FOSRENOL and Renagel

Shire plc, the global specialty biopharmaceutical company, today announces the publication in Clinical Nephrology of findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, FOSRENOL(R) (lanthanum carbonate) and sevelamer hydrochloride (Genzyme's Renagel(R)) in chronic kidney disease (CKD) patients on haemodialysis.

7 Oct 2009

Pharmaceutical companies gearing up for cancer vaccine trials following FDA draft guidance

Pharmaceutical companies are gearing up for an increase in running late phase cancer vaccine trials following draft guidance issued by the FDA last week.

From AES - Accelerated Enrollment Solutions 7 Oct 2009

Impax Laboratories settles FLOMAX litigation, to launch generic tamsulosin hydrochloride product

Impax Laboratories, Inc. today announced that it has reached agreement with Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. to settle pending U.S. litigation with regard to US Patent No. 4,703,063 for FLOMAX® (generic name: tamsulosin hydrochloride) capsules through the entry of a consent judgment confirming the validity and infringement of the patent. FLOMAX® is a treatment for the functional symptoms of benign prostatic hyperplasia.

7 Oct 2009

Promotional speaker programs on the latest drug developments help pharma companies attract physicians

In response to increased political and regulatory scrutiny, pharmaceutical companies are rebranding their promotional speaker programs as unparalleled opportunities for physicians to learn or remain current on the latest drug developments and to network with colleagues. The rebranding is helping to attract physicians who are more interested in learning than in getting a free meal. It is also working to improve program ROI and lessen pressures from outside agencies that feel the meetings are payoffs for prescriptions.

7 Oct 2009

HTDS receives follow up report and files with Pink Sheets

HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing,

7 Oct 2009

aTyr Pharma to discuss aminoacyl tRNA synthetases at the BioPartnering Europe Conference

aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring proteins as biotherapeutics, will present at the BioPartnering Europe Conference in London on Monday October 12. Jeff Watkins, CEO of aTyr Pharma, will provide an overview of aTyr Pharma's technology, product engine, and lead program based on naturally occurring resected proteins of the tRNA synthetases.

7 Oct 2009

Werum Software & Systems opens new subsidiary in France

On October 1st, German software provider Werum Software & Systems AG officially opened its new subsidiary Werum Software & Systems SAS in France.

7 Oct 2009

Uncertainty regarding clinical effectiveness is a key issue in coverage decisions: Study

A comparison of national agencies that play a role in determining drug coverage decisions in Britain, Canada and Australia finds that uncertainty regarding clinical effectiveness is a key issue in coverage decisions, with other factors including the ability to negotiate price and societal values, according to a study in the October 7 issue of JAMA.

7 Oct 2009

Allsup: Disabled people experience difficulty in receiveing much-needed treatment

People with disabilities have crucial healthcare needs, but often experience difficulty in receiving much-needed treatment, according to Allsup, a nationwide provider of Social Security disability representation and Medicare services.

7 Oct 2009

Fully validated assay to detect the presence of Calicivirus 2117 in biological samples

BioReliance Corporation announced today that it has launched a fully validated assay which can sensitively detect the presence of Calicivirus 2117 in biological samples. The test is designed to provide manufacturers of biological therapeutics and other biologically based products the ability to detect this potential contaminant of mammalian cell culture based systems.

7 Oct 2009

Repros announces results of its Androxal efficacy study for secondary hypogonadism

Repros Therapeutics Inc. today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.

7 Oct 2009

Pharmaceuticals News and Research

Biostar Pharmaceuticals' new drug application granted clearance for clinical trials

Cipher Pharmaceuticals enrolls first patient in Phase III study of CIP-ISOTRETINOIN

Arizona Heart Institute partners with Arizona Research Center for the advancement of cardiovascular therapies

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Aryx Therapeutics to raise up to $35 million from sale of its common stock

Tranziger forms global advisory and business team to execute strategic transactions

Roche and Genentech obtain license to use SurModics’ drug delivery system

CBI announces agenda for upcoming Biotech/Pharma Finance and Accounting Forum in San Francisco

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Shire publishes efficacy study results of FOSRENOL and Renagel

Pharmaceutical companies gearing up for cancer vaccine trials following FDA draft guidance

Impax Laboratories settles FLOMAX litigation, to launch generic tamsulosin hydrochloride product

Promotional speaker programs on the latest drug developments help pharma companies attract physicians

HTDS receives follow up report and files with Pink Sheets

aTyr Pharma to discuss aminoacyl tRNA synthetases at the BioPartnering Europe Conference

Werum Software & Systems opens new subsidiary in France

Uncertainty regarding clinical effectiveness is a key issue in coverage decisions: Study

Allsup: Disabled people experience difficulty in receiveing much-needed treatment

Fully validated assay to detect the presence of Calicivirus 2117 in biological samples

Repros announces results of its Androxal efficacy study for secondary hypogonadism

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring